Harry Flore, PhD

P.H. (Harry) Flore was born in Indonesia, and educated in Australia and in The Netherlands where he studied cell biology and finished a PhD in virology at the Agricultural University in Wageningen. He then held a postdoctoral position at Cornell University in New York for three years, designing novel vaccine strategies, after which he joined Solvay-Duphar in Weesp, The Netherlands, developing veterinary vaccines.

After 10 years he moved on to Lohmann Animal Health in Cuxhaven, Germany as R&D Director for veterinary vaccines. He founded a Contract Manufacturing Organisation (now named Vibalogics) before moving on as General Manager to the Central Veterinary Institute in Lelystad, which is part of the Wageningen University Research Centre (WUR).

Next he was Chief Executive Officer (CEO) of HAL Allergy in Leiden, The Netherlands. He co-founded the Contract Development and Manufacturing Organization HALIX, part of HAL Allergy Holding. HALIX is specialized in protein and virus manufacturing under BSL2/3 conditions in a GMP environment.

Currently he is Chairman of the Supervisory Board of HAL Allergy Holding, HAL Allergy and HALIX. In addition, he is Scientific Advisor / Board Member in several research companies and organizations involved in biotechnological research and production, including Intravacc, CimCure, Bioneedle Drug Delivery, Biotech Training Facility and ISTAB – Hochschule Bremen, Germany.